Is Minerva Surgical, Inc. overvalued or undervalued?

As of 11 May 2022, the valuation grade for Minerva Surgical, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, with a P/E ratio of 0.00, an EV to EBIT of -0.85, and an EV to EBITDA of -1.14. These figures suggest that the company is not generating positive earnings or cash flow, which is concerning for potential investors.
In comparison to its peers, Minerva Surgical's financial ratios are notably poor. For instance, Artivion, Inc. has a P/E ratio of -111.78, while Silk Road Medical, Inc. stands at -19.76, both of which reflect similar risks in their valuations. The stark contrast in performance is further highlighted by Minerva's return of -99.09% over the past year compared to the S&P 500's 10.26% return, reinforcing the notion that the company is not only struggling but also potentially overvalued in the current market environment.